Braveheart Bio, Inc. (BRVE)

NASDAQ: BRVE · Real-Time Price · USD

26.95

+0.67 (2.55%)

Sep 2, 2026, 4:00 PM EDT - Market closed

Braveheart Bio Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Operating Activities

Fiscal Year	TTM	FY 2025
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025
Net Income	-80.23	-66.05
Asset Writedown & Restructuring Costs	62.15	62.24
Stock-Based Compensation	1.93	0.18
Change in Accounts Payable	7.77	0.9
Change in Other Net Operating Assets	1.18	0.72
Operating Cash Flow	-7.2	-2.01
Operating Cash Flow Growth	-	-

Investing Activities

Fiscal Year	TTM	FY 2025
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025
Sale (Purchase) of Intangibles	-36.57	-33.57
Investing Cash Flow	-36.61	-33.57

Financing Activities

Fiscal Year	TTM	FY 2025
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025
Issuance of Common Stock	0.1	0.1
Financing Cash Flow	124.38	124.74

Net Cash Flow

Fiscal Year	TTM	FY 2025
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025
Net Cash Flow	80.58	89.16

Additional Metrics

Fiscal Year	TTM	FY 2025
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025
Change in Working Capital	8.95	1.62

SEC Filings: 10-K · 10-Q